BRPI0515560A - memantina para o tratamento de distúrbios comportamentais infantis - Google Patents

memantina para o tratamento de distúrbios comportamentais infantis

Info

Publication number
BRPI0515560A
BRPI0515560A BRPI0515560-6A BRPI0515560A BRPI0515560A BR PI0515560 A BRPI0515560 A BR PI0515560A BR PI0515560 A BRPI0515560 A BR PI0515560A BR PI0515560 A BRPI0515560 A BR PI0515560A
Authority
BR
Brazil
Prior art keywords
memantine
treatment
behavioral disorders
childhood
childhood behavioral
Prior art date
Application number
BRPI0515560-6A
Other languages
English (en)
Inventor
Jeffrey Jonas
Pradeep K Banerjee
Sandeep Gupta
Allison Mann
Hans-Joerg Moebius
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35445934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0515560(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BRPI0515560A publication Critical patent/BRPI0515560A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"MEMANTINA PARA O TRATAMENTO DE DISTúRBIOS COMPORTAMENTAIS INFANTIS". A presente invenção fornece um método para o tratamento de indivíduos diagnosticados com um distúrbio comportamental infantil ou distúrbio combinado do tipo deficiência de atenção/hiperatividade (ADHD), pela administração de uma quantidade eficaz de memantina.
BRPI0515560-6A 2004-09-23 2005-09-23 memantina para o tratamento de distúrbios comportamentais infantis BRPI0515560A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61260004P 2004-09-23 2004-09-23
PCT/US2005/034199 WO2006034465A1 (en) 2004-09-23 2005-09-23 Memantine for the treatment of childhood behavioral disorders

Publications (1)

Publication Number Publication Date
BRPI0515560A true BRPI0515560A (pt) 2008-07-29

Family

ID=35445934

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515560-6A BRPI0515560A (pt) 2004-09-23 2005-09-23 memantina para o tratamento de distúrbios comportamentais infantis

Country Status (16)

Country Link
US (2) US20060079582A1 (pt)
EP (1) EP1799224A1 (pt)
JP (1) JP2008514620A (pt)
KR (1) KR20070046185A (pt)
CN (1) CN101374525A (pt)
AR (1) AR052643A1 (pt)
AU (1) AU2005286672B2 (pt)
BR (1) BRPI0515560A (pt)
CA (1) CA2578953A1 (pt)
EA (1) EA012036B1 (pt)
IL (1) IL182105A0 (pt)
MX (1) MX2007003267A (pt)
NO (1) NO20072035L (pt)
TW (1) TW200626160A (pt)
WO (1) WO2006034465A1 (pt)
ZA (1) ZA200702130B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456224B2 (en) 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
US20080008743A1 (en) * 2006-07-06 2008-01-10 Forest Laboratories Holdings Limited Orally Dissolving Formulations of Memantine
RU2326660C1 (ru) * 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
EP2170310A4 (en) * 2007-06-29 2010-06-23 Orchid Chemicals & Pharm Ltd FAST-DISSOLVING COMPOSITIONS OF MEMANTINE HYDROCHLORIDE
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
SI2201950T1 (sl) * 2008-12-08 2017-05-31 Biocodex Spojine in metode za zdravljenje motenj avtističnega spektra
IT1396556B1 (it) 2009-02-11 2012-12-14 Serra Uso di memantina per il trattamento di disturbi dell umore
JP5916746B2 (ja) 2010-11-15 2016-05-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのピリダジン誘導体、組成物、および方法
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
US9242009B2 (en) 2012-07-17 2016-01-26 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
KR101424514B1 (ko) * 2013-01-02 2014-07-31 건국대학교 산학협력단 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도
EP2948135B1 (en) * 2013-01-25 2019-01-02 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
WO2014153180A1 (en) * 2013-03-14 2014-09-25 Michela Gallagher Methods and compositions for improving cognitive function
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN106068256B (zh) 2013-12-20 2020-10-23 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
CN114366759A (zh) * 2015-05-22 2022-04-19 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
MX2019001799A (es) 2016-08-24 2019-06-13 Zogenix International Ltd Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
KR20200043401A (ko) * 2017-08-01 2020-04-27 스튜어트 에이. 립튼 신경 질환을 치료하기 위한 방법 및 조성물
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
CA3081604A1 (en) 2017-11-22 2019-05-31 Panorama Research, Inc. Aminoadamantyl nitrate compounds and their use to treat cns disorders
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
JP7514534B2 (ja) 2018-06-19 2024-07-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (pt) * 1972-04-20 1973-10-23
HU169986B (pt) * 1972-12-07 1977-03-28
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4849222A (en) * 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
DE58905637D1 (de) * 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US6326226B1 (en) * 1997-07-15 2001-12-04 Lg. Philips Lcd Co., Ltd. Method of crystallizing an amorphous film
JP4562911B2 (ja) * 1998-01-13 2010-10-13 シンクロニュ−ロン，エルエルシ− 遅発性ジスキネジア及び他の運動障害の治療方法
AU4517201A (en) * 1999-12-08 2001-06-18 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
WO2003061656A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
AU2003251993A1 (en) * 2002-07-19 2004-02-09 Inge Grundke-Iqbal NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease

Also Published As

Publication number Publication date
ZA200702130B (en) 2008-09-25
NO20072035L (no) 2007-06-13
CN101374525A (zh) 2009-02-25
AR052643A1 (es) 2007-03-28
WO2006034465A1 (en) 2006-03-30
US20100081723A1 (en) 2010-04-01
US20060079582A1 (en) 2006-04-13
EA012036B1 (ru) 2009-06-30
AU2005286672A1 (en) 2006-03-30
JP2008514620A (ja) 2008-05-08
IL182105A0 (en) 2007-07-24
EP1799224A1 (en) 2007-06-27
AU2005286672B2 (en) 2009-03-12
MX2007003267A (es) 2007-05-23
EA200700708A1 (ru) 2007-08-31
KR20070046185A (ko) 2007-05-02
CA2578953A1 (en) 2006-03-30
TW200626160A (en) 2006-08-01
WO2006034465A8 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
BRPI0515560A (pt) memantina para o tratamento de distúrbios comportamentais infantis
BR112018008358A2 (pt) ?composições e métodos para terapia relacionada à microbiota fecal?
CY1112953T1 (el) Χρηση των αντι-cd100 αντισωματων
BRPI0607307A2 (pt) compostos e composições como inibidores de proteìna cinase
BRPI0509207A (pt) moduladores canabinóides de tetraidro-indazol
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
TW200517114A (en) Methods and reagents for the treatment of immunoinflammatory disorders
BRPI0410041A (pt) métodos para tratamento de dor de cabeça de sinusite
BRPI0514395A (pt) uso terapêutico de inibidores de rtp801
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
BR112012012610A2 (pt) terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma
AR064456A1 (es) Anticuerpos cd 44
BRPI0607094A2 (pt) composto da fórmula i; uso do composto para o tratamento de uma doença ou distúrbio associado à atividade excessiva de bace em um paciente que dele necessita; uso do composto para modular a atividade de bace; e composição farmacêutica
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
BRPI0512856A (pt) métodos e reagentes para o tratamento de distúrbios metabólicos
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
WO2007089617A3 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
CY1123240T1 (el) Αντισωμα αντι fgf23 και μια φαρμακευτικη συνθεση που το περιλαμβανει
WO2007100777A3 (en) Methods for the treatment of adhd and related disorders
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
BR112014012746A2 (pt) nanoveículos de diagnóstico e/ou terapêutica direcionada por mmp
NO20083751L (no) Metoder for behandling av kognitive og andre sykdommer
BR112015030099A2 (pt) marcador para desordens de esfingomielinase ácida e usos do mesmo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.